Shineco Inc. Partners with Plus Me for Groundbreaking Blockchain Initiative

In a significant move that underscores its commitment to innovation, Shineco Inc., a biotechnology-driven consumer staples company, has announced a strategic partnership with Plus Me Limited. This collaboration aims to pioneer blockchain-based tokenization of biological cellular assets, marking a transformative step in the global biotech and blockchain industries.

A Revolutionary Approach to Cell Tokenization

Shineco, known for its expertise in developing biological health products, including Chinese herbal medicines and specialized textiles, is now venturing into the realm of blockchain technology. The partnership with Plus Me Limited will enable the tokenization of biological cellular assets, specifically mesenchymal stem cells (MSCs), on the Ethereum mainnet. This initiative is set to revolutionize the way biological assets are transferred and managed globally.

The “Cellular Asset On-Chaining and Marketing Ecosystem Cooperation Agreement” will facilitate the creation of a novel ‘Asset On-Chaining + Application Scenarios’ model in cell therapy. By leveraging blockchain technology, Shineco and Plus Me aim to redefine the commercial architecture of the global biological cell industry. The partnership will ensure seamless global transfers and auditable standardized custody of cellular assets, enhancing traceability and compliance through cryptographically enforced on-chain hashing.

Enhancing Traceability and Compliance

One of the standout features of this initiative is the issuance of unique non-fungible digital identifiers (NFDIs) for each cellular asset. These identifiers will ensure the verifiable uniqueness and regulatory compliance of the assets, addressing a critical need in the biotech industry for secure and transparent asset management. The use of smart contracts will immutably secure asset ownership rights, further bolstering the integrity of the tokenization process.

Introducing Cell Infusion Redemption Tokens

In addition to the technical advancements, the partnership will see the issuance of ERC-1400/ERC-20 compliant security tokens, branded as “Cell Infusion Redemption Tokens.” These utility tokens represent a novel approach to accessing cell therapy services, as they can be redeemed at Shineco-affiliated Cell Therapy Centers. This initiative not only enhances the accessibility of cell therapy but also integrates blockchain technology into the healthcare sector, offering a glimpse into the future of medical treatments.

A Strategic Move with Global Implications

The collaboration between Shineco and Plus Me Limited is more than just a technological advancement; it’s a strategic move that positions Shineco at the forefront of the intersection between biotechnology and blockchain. By expanding its global blockchain-biotech network through this strategic acquisition, Shineco is set to redefine industry standards and pave the way for future innovations in the biotech sector.

As Shineco continues to push the boundaries of what’s possible in the biotech and blockchain industries, this partnership with Plus Me Limited highlights the company’s commitment to innovation and its vision for a future where technology and biology converge to create groundbreaking solutions. With its shares closing at $4.95 on August 18, 2025, and a market cap of $4,458,019, Shineco’s strategic initiatives are closely watched by investors and industry insiders alike, signaling a promising trajectory for the company and its stakeholders.